RO-7071759
Dry Eye Disease (DED)
Phase 2Active
Key Facts
About Rohto Pharmaceutical
Founded in 1899, Rohto Pharmaceutical has built a dominant global franchise in consumer healthcare, particularly in eye drops and skincare, generating stable revenues and deep consumer trust. The company's core strategy involves using this financial strength to fund a strategic pivot into biopharmaceutical R&D, with a focused pipeline in ophthalmology, dermatology, and metabolic diseases. Its achievements include a formidable OTC brand portfolio, international distribution, and the advancement of several drug candidates, positioning it for long-term growth beyond its traditional market.
View full company profileTherapeutic Areas
Other Dry Eye Disease (DED) Drugs
| Drug | Company | Phase |
|---|---|---|
| Licaminlimab (OCS-02) | Oculis | Phase 2/3 |
| PRP/Excipient Formulation | ECI Therapeutics | Pre-clinical |
| ALG-1007 | Allegro Ophthalmics | Pre-clinical/Phase 1 |
| SLG-100 | Selagine | Clinical Stage (Pilot trial completed) |
| Carragelose® Eyedrops | Unither Pharmaceuticals | Commercial (Out-licensing) |
| Urcosimod (OK-101) | OKYO Pharma | Phase 2 |